# Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

> **NCT00022945** · PHASE2 · COMPLETED · sponsor: **Corixa Corporation**

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Iodine-131 Anti-B1 Antibody
- **DRUG:** Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)

## Key facts

- **NCT ID:** NCT00022945
- **Lead sponsor:** Corixa Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022945, "Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00022945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*